NovoCure Limited (FRA:038)

NovoCure Statistics

Total Valuation

NovoCure has a market cap or net worth of EUR 1.13 billion. The enterprise value is 922.47 million.

Market Cap	1.13B
Enterprise Value	922.47M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	111.98M
Shares Outstanding	n/a
Shares Change (YoY)	+2.82%
Shares Change (QoQ)	+0.30%
Owned by Insiders (%)	9.68%
Owned by Institutions (%)	73.63%
Float	91.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.06
PB Ratio	3.87
P/TBV Ratio	3.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.09
EV / Sales	1.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.61

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 2.34.

Current Ratio	1.55
Quick Ratio	1.49
Debt / Equity	2.34
Debt / EBITDA	n/a
Debt / FCF	-12.24
Interest Coverage	-12.54

Financial Efficiency

Return on equity (ROE) is -50.60% and return on invested capital (ROIC) is -9.85%.

Return on Equity (ROE)	-50.60%
Return on Assets (ROA)	-8.30%
Return on Invested Capital (ROIC)	-9.85%
Return on Capital Employed (ROCE)	-29.30%
Revenue Per Employee	367,880
Profits Per Employee	-101,755
Employee Count	1,488
Asset Turnover	0.50
Inventory Turnover	4.02

Taxes

In the past 12 months, NovoCure has paid 23.14 million in taxes.

Income Tax	23.14M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -36.44% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-36.44%
50-Day Moving Average	10.81
200-Day Moving Average	13.16
Relative Strength Index (RSI)	56.44
Average Volume (20 Days)	17

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.62

Income Statement

In the last 12 months, NovoCure had revenue of EUR 547.41 million and -151.41 million in losses. Loss per share was -1.37.

Revenue	547.41M
Gross Profit	413.44M
Operating Income	-146.13M
Pretax Income	-128.27M
Net Income	-151.41M
EBITDA	-135.76M
EBIT	-146.13M
Loss Per Share	-1.37

Balance Sheet

The company has 880.85 million in cash and 680.09 million in debt, giving a net cash position of 200.77 million.

Cash & Cash Equivalents	880.85M
Total Debt	680.09M
Net Cash	200.77M
Net Cash Per Share	n/a
Equity (Book Value)	290.92M
Book Value Per Share	2.60
Working Capital	361.25M

Cash Flow

In the last 12 months, operating cash flow was -29.39 million and capital expenditures -26.16 million, giving a free cash flow of -55.55 million.

Operating Cash Flow	-29.39M
Capital Expenditures	-26.16M
Free Cash Flow	-55.55M
FCF Per Share	n/a

Margins

Gross margin is 75.53%, with operating and profit margins of -26.70% and -27.66%.

Gross Margin	75.53%
Operating Margin	-26.70%
Pretax Margin	-23.43%
Profit Margin	-27.66%
EBITDA Margin	-24.80%
EBIT Margin	-26.70%
FCF Margin	n/a

Dividends & Yields

NovoCure does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.82%
Shareholder Yield	-2.82%
Earnings Yield	-13.46%
FCF Yield	-4.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NovoCure has an Altman Z-Score of 0.33 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.33
Piotroski F-Score	3